One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine

Tzou Yien Lin, Ying Hsiang Wang, Yhu Chering Huang, Cheng Hsun Chiu, Pen Yi Lin, Chih Jung Chen, Pascale Chavand, Esteban Ortiz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To evaluate antibody persistence one year after three-dose primary vaccination and booster immune response during the second year of life for a fully liquid diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-PRP∼T) vaccine. Methods: Infants at 18-19 months of age were given a booster dose of either DTaP-IPV-PRP∼T (group A) or DTaP-IPV plus PRP∼T at separate injection sites (group B), after primary vaccination at two, four and six months of age, with the same vaccines. Antibody concentrations were measured pre- and post-booster. Reactogenicity and safety were evaluated from parent reports. Results: Before the booster dose, 93.1% of group A and 95.1% of group B children still had anti-PRP antibody titers ≥0.15 μg/ml. All children had antibody levels believed to protect against tetanus, polio 1 (except one subject in group B), polio 2, polio 3, and diphtheria (except one subject in group A). At least 94% of children still had antibody concentrations ≥5 ELISA units (EU) to pertussis antigens (pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae 2 and 3 (FIM2+3)). One month after the booster dose, all subjects achieved antibody concentrations or titers believed to be protective for PRP (polyribose ribitol phosphate)(≥1 μg/ml), diphtheria and tetanus (≥0.1 IU/ml) and poliovirus types 1, 2, and 3 (≥8 1/dil.), and at least 90.5% of subjects had four-fold increases in antibody concentrations to pertussis antigens following the booster. Anti-PRP geometric mean titers (GMTs) increased from 1.07 to 59.6 μg/ml and from 1.8 to 62.2 μg/ml in groups A and B, respectively. Both vaccine groups showed low reactogenicity rates. Conclusions: The fully liquid pentavalent DTaP-IPV-PRP∼T vaccine is highly immunogenic, with good antibody persistence for each antigen approximately one year after primary vaccination and strong booster responses at 18-19 months of age. Because this combined vaccine is fully liquid, requiring no reconstitution of lyophilized PRP∼T, the ease of use and proper administration are improved.

Original languageEnglish
Pages (from-to)488-495
Number of pages8
JournalInternational Journal of Infectious Diseases
Volume11
Issue number6
DOIs
Publication statusPublished - Nov 2007
Externally publishedYes

Fingerprint

Antibodies
Poliomyelitis
Diphtheria
Poliovirus
Whooping Cough
Tetanus
Vaccines
Vaccination
Antigens
Combined Vaccines
Haemophilus influenzae type b
diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine
Hemagglutinins
Enzyme-Linked Immunosorbent Assay
Safety
Injections
polyribitol phosphate

Keywords

  • Acellular pertussis
  • Antibody persistence
  • Booster response
  • Fully liquid pentavalent vaccine
  • Haemophilus influenzae type b
  • Inactivated polio vaccine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. / Lin, Tzou Yien; Wang, Ying Hsiang; Huang, Yhu Chering; Chiu, Cheng Hsun; Lin, Pen Yi; Chen, Chih Jung; Chavand, Pascale; Ortiz, Esteban.

In: International Journal of Infectious Diseases, Vol. 11, No. 6, 11.2007, p. 488-495.

Research output: Contribution to journalArticle

@article{4842e1edcac7405b99506373486426f3,
title = "One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine",
abstract = "Objective: To evaluate antibody persistence one year after three-dose primary vaccination and booster immune response during the second year of life for a fully liquid diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-PRP∼T) vaccine. Methods: Infants at 18-19 months of age were given a booster dose of either DTaP-IPV-PRP∼T (group A) or DTaP-IPV plus PRP∼T at separate injection sites (group B), after primary vaccination at two, four and six months of age, with the same vaccines. Antibody concentrations were measured pre- and post-booster. Reactogenicity and safety were evaluated from parent reports. Results: Before the booster dose, 93.1{\%} of group A and 95.1{\%} of group B children still had anti-PRP antibody titers ≥0.15 μg/ml. All children had antibody levels believed to protect against tetanus, polio 1 (except one subject in group B), polio 2, polio 3, and diphtheria (except one subject in group A). At least 94{\%} of children still had antibody concentrations ≥5 ELISA units (EU) to pertussis antigens (pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae 2 and 3 (FIM2+3)). One month after the booster dose, all subjects achieved antibody concentrations or titers believed to be protective for PRP (polyribose ribitol phosphate)(≥1 μg/ml), diphtheria and tetanus (≥0.1 IU/ml) and poliovirus types 1, 2, and 3 (≥8 1/dil.), and at least 90.5{\%} of subjects had four-fold increases in antibody concentrations to pertussis antigens following the booster. Anti-PRP geometric mean titers (GMTs) increased from 1.07 to 59.6 μg/ml and from 1.8 to 62.2 μg/ml in groups A and B, respectively. Both vaccine groups showed low reactogenicity rates. Conclusions: The fully liquid pentavalent DTaP-IPV-PRP∼T vaccine is highly immunogenic, with good antibody persistence for each antigen approximately one year after primary vaccination and strong booster responses at 18-19 months of age. Because this combined vaccine is fully liquid, requiring no reconstitution of lyophilized PRP∼T, the ease of use and proper administration are improved.",
keywords = "Acellular pertussis, Antibody persistence, Booster response, Fully liquid pentavalent vaccine, Haemophilus influenzae type b, Inactivated polio vaccine",
author = "Lin, {Tzou Yien} and Wang, {Ying Hsiang} and Huang, {Yhu Chering} and Chiu, {Cheng Hsun} and Lin, {Pen Yi} and Chen, {Chih Jung} and Pascale Chavand and Esteban Ortiz",
year = "2007",
month = "11",
doi = "10.1016/j.ijid.2007.01.006",
language = "English",
volume = "11",
pages = "488--495",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine

AU - Lin, Tzou Yien

AU - Wang, Ying Hsiang

AU - Huang, Yhu Chering

AU - Chiu, Cheng Hsun

AU - Lin, Pen Yi

AU - Chen, Chih Jung

AU - Chavand, Pascale

AU - Ortiz, Esteban

PY - 2007/11

Y1 - 2007/11

N2 - Objective: To evaluate antibody persistence one year after three-dose primary vaccination and booster immune response during the second year of life for a fully liquid diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-PRP∼T) vaccine. Methods: Infants at 18-19 months of age were given a booster dose of either DTaP-IPV-PRP∼T (group A) or DTaP-IPV plus PRP∼T at separate injection sites (group B), after primary vaccination at two, four and six months of age, with the same vaccines. Antibody concentrations were measured pre- and post-booster. Reactogenicity and safety were evaluated from parent reports. Results: Before the booster dose, 93.1% of group A and 95.1% of group B children still had anti-PRP antibody titers ≥0.15 μg/ml. All children had antibody levels believed to protect against tetanus, polio 1 (except one subject in group B), polio 2, polio 3, and diphtheria (except one subject in group A). At least 94% of children still had antibody concentrations ≥5 ELISA units (EU) to pertussis antigens (pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae 2 and 3 (FIM2+3)). One month after the booster dose, all subjects achieved antibody concentrations or titers believed to be protective for PRP (polyribose ribitol phosphate)(≥1 μg/ml), diphtheria and tetanus (≥0.1 IU/ml) and poliovirus types 1, 2, and 3 (≥8 1/dil.), and at least 90.5% of subjects had four-fold increases in antibody concentrations to pertussis antigens following the booster. Anti-PRP geometric mean titers (GMTs) increased from 1.07 to 59.6 μg/ml and from 1.8 to 62.2 μg/ml in groups A and B, respectively. Both vaccine groups showed low reactogenicity rates. Conclusions: The fully liquid pentavalent DTaP-IPV-PRP∼T vaccine is highly immunogenic, with good antibody persistence for each antigen approximately one year after primary vaccination and strong booster responses at 18-19 months of age. Because this combined vaccine is fully liquid, requiring no reconstitution of lyophilized PRP∼T, the ease of use and proper administration are improved.

AB - Objective: To evaluate antibody persistence one year after three-dose primary vaccination and booster immune response during the second year of life for a fully liquid diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-PRP∼T) vaccine. Methods: Infants at 18-19 months of age were given a booster dose of either DTaP-IPV-PRP∼T (group A) or DTaP-IPV plus PRP∼T at separate injection sites (group B), after primary vaccination at two, four and six months of age, with the same vaccines. Antibody concentrations were measured pre- and post-booster. Reactogenicity and safety were evaluated from parent reports. Results: Before the booster dose, 93.1% of group A and 95.1% of group B children still had anti-PRP antibody titers ≥0.15 μg/ml. All children had antibody levels believed to protect against tetanus, polio 1 (except one subject in group B), polio 2, polio 3, and diphtheria (except one subject in group A). At least 94% of children still had antibody concentrations ≥5 ELISA units (EU) to pertussis antigens (pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae 2 and 3 (FIM2+3)). One month after the booster dose, all subjects achieved antibody concentrations or titers believed to be protective for PRP (polyribose ribitol phosphate)(≥1 μg/ml), diphtheria and tetanus (≥0.1 IU/ml) and poliovirus types 1, 2, and 3 (≥8 1/dil.), and at least 90.5% of subjects had four-fold increases in antibody concentrations to pertussis antigens following the booster. Anti-PRP geometric mean titers (GMTs) increased from 1.07 to 59.6 μg/ml and from 1.8 to 62.2 μg/ml in groups A and B, respectively. Both vaccine groups showed low reactogenicity rates. Conclusions: The fully liquid pentavalent DTaP-IPV-PRP∼T vaccine is highly immunogenic, with good antibody persistence for each antigen approximately one year after primary vaccination and strong booster responses at 18-19 months of age. Because this combined vaccine is fully liquid, requiring no reconstitution of lyophilized PRP∼T, the ease of use and proper administration are improved.

KW - Acellular pertussis

KW - Antibody persistence

KW - Booster response

KW - Fully liquid pentavalent vaccine

KW - Haemophilus influenzae type b

KW - Inactivated polio vaccine

UR - http://www.scopus.com/inward/record.url?scp=35448988572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448988572&partnerID=8YFLogxK

U2 - 10.1016/j.ijid.2007.01.006

DO - 10.1016/j.ijid.2007.01.006

M3 - Article

VL - 11

SP - 488

EP - 495

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

SN - 1201-9712

IS - 6

ER -